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The opportunity of a multidisciplinary evaluation for the diagnosis of interstitial
pneumonias highlighted a major change in the diagnostic approach to diffuse lung
disease. The new American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Latin American Thoracic Society guidelines for the diagnosis
of idiopathic pulmonary fibrosis have reinforced this assumption and have underlined
that the exclusion of connective tissue disease related lung involvement is mandatory,
with obvious clinical and therapeutic impact. The multidisciplinary team discussion
consists in amoment of interaction among the radiologist, pathologist and pulmonologist,
also including the rheumatologist when considered necessary, to improve diagnostic
agreement and optimize the definition of those cases in which pulmonary involvement
may represent the first or prominent manifestation of an autoimmune systemic
disease. Moreover, the proposal of classification criteria for interstitial lung disease with
autoimmune features (IPAF) represents an effort to define lung involvement in clinically
undefined autoimmune conditions. The complexity of autoimmune diseases, and in
particular the lack of classification criteria defined for pathologies such as anti-synthetase
syndrome, makes the involvement of the rheumatologist essential for the correct
interpretation of the autoimmune element and for the application of classification criteria,
that could replace clinical pictures initially interpreted as IPAF in defined autoimmune
disease, minimizing the risk of misdiagnosis. The aim of this review was to evaluate the
available evidence about the efficiency and efficacy of different multidisciplinary team
approaches, in order to standardize the professional figures and the core set procedures
that should be necessary for a correct approach in diagnosing patients with interstitial
lung disease.
Keywords: interstitial lung disease (ILD), connective tissue disease (CTD), multidisciplinary team (MDT),
rheumatologist, interstitial pneumonia with autoimmune features (IPAF)
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INTRODUCTION
Multidisciplinary discussion (MDD) is currently recommended
during the diagnostic process of interstitial lung diseases (ILD) in
particular when idiopathic pulmonary fibrosis (IPF) is suspected
(1, 2). IPF has the worst prognosis among the different forms
of ILD, with a median survival of 3–5 years from the diagnosis.
It can generally be suspected in male subjects over the age
of 60 who present an usual interstitial pneumonia pattern
(UIP) at radiology and histology. In subjects with a radiological
pattern compatible with UIP and in the absence of a detectable
etiology, surgical lung biopsy (SLB) is not necessary, whereas it
should be considered in patients with probable or indeterminate
radiological patterns for UIP especially when an alternative
diagnosis is not achievable (1). MDD is currently replacing the
histological evaluation, due to its limited reliability and intrinsic
risks particularly in elderly or highly comorbid patients (3).
Given the poor prognosis of IPF and the availability of new anti-
fibrotic drugs such as pirfenidone and nintedanib, the diagnosis
formulated via MDD is currently considered the gold standard
(4–6). Despite this guideline for IPF diagnosis, there are no
available studies that clearly assess the impact ofmultidisciplinary
team (MDT) in the approach to patients with ILD and we do
not know if the evaluation by experts can actually be better than
MDD. Nonetheless, the participation by clinicians, radiologists,
and when applicable histopathologists, could be considered
useful to share clinical cases between physicians with different
points of view in order to establish a “common language” and
improve the knowledge of the singles (7).
Applying the guidelines of the American Thoracic Society,
European Respiratory Society, Japanese Respiratory Society and
Latin American Thoracic Association (ATS/ERS/JRS/ALAT),
the recommended MDT is generally composed by a clinician
(often a pulmonologist), a thoracic radiologist and pathologist
with experience in ILD. Other physicians as rheumatologist
should be considered only in selected cases (8). Current clinical
practice guidelines for IPF recommend to perform a battery
of serological test as C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), antinuclear antibodies (ANA) by
immunofluorescence, rheumatoid factor (RF), myositis panel,
and anti–cyclic citrullinated peptide (ACPA) without a previous
consultation with rheumatologist, reserving this possibility in
case of positivity of serological tests or presence of clinical
manifestations suggesting an underling rheumatological disease
(especially in women <60 years old) (8).
Hence ILD could be related to rheumatoid arthritis (RA),
systemic vasculitis (especially antineutrophil Cytoplasmic
Antibodies (ANCA)-associated Vasculitis) (9) and different
connective tissue disease (CTD) especially systemic sclerosis
(SSc), myositis spectrum disorders comprising overlap myositis
and antisynthetase syndrome (ASSD) but also systemic lupus
erythematosus, primary Sjoġren’s syndrome, and mixed CTD
(10, 11). Specific classification criteria are available for most
CTDs, while classification criteria currently lack for diseases such
as ASSD, making the correct diagnosis very challenging (12).
The recent introduction of criteria defining interstitial
pneumonias with autoimmune features (IPAF) has allowed
to reclassify those ILD that did not meet any CTD criteria,
creating a growing interest in research concerning these new
entities, especially on their possible evolution in CTD and overall
prognosis (13).
The primary objective of this study was to perform a
systematic review of literature to explore the evidence on
the organization and outcome of MDT for the diagnosis and
management of ILD, and to evaluate the role of rheumatologist.
A secondary objective is to elaborate a definite proposal of ILD
multidisciplinary evaluation.
MATERIALS AND METHODS
A systematic literature review was performed using electronic
databases Pubmed (1999–2019) and Embase (1999–2019).
The search strategy was elaborated to include the greatest
number of references dealing with the populations and the
interventions object of the study by using the following keywords
in combination with the Boolean operators OR and AND:
“interstitial,” “pneumonia,” “multidisciplinary,” “lung disease,
interstitial,” “pulmonary fibrosis,” “interstitial pneumonias,”
“multidisciplinary team,” and “multidisciplinary approach.”
Three reviewers (FF, GG, and AC) independently screened
the titles and abstracts of all retrieved papers and selected the
studies to be included in this review, after removing duplicates.
All the articles selected by at least one of the reviewers were
retrieved for full text evaluation. Article were selected according
a priori inclusion criteria according to PICO methodology:
(a) population: subjects aged>18 years with a suspected or
established diagnosis of ILD; (b) intervention: multidisciplinary
approach involving at least two different physicians of two
different specialties; (c) type of study: metanalysis, randomized
controlled trial (RCT), cohort, case control and case series (>5
patients) in English language. Other languages and other study
designs (narrative review, case reports and meeting abstracts)
were excluded. In case of disagreement between the reviewers,
a further author (CS) was consulted to achieve a consensus.
Primary outcome of this systematic review was the definition
of the organization and physicians involved in the MDT with
particular attention to clinical data collected and instrumental
exams performed. A secondary objective was to evaluate
the outcome of multidisciplinary approach (e.g., diagnosis or
management) and to evaluate the role of rheumatologist. Selected
articles were reviewed independently by three reviewers (FF, GG,
and AC) and all data were extracted using an extraction form
designed to respond to primary and secondary objectives of the
review. The following data were extracted: authors, journal, year
of publication, study design, inclusion and exclusion criteria,
number of participants, population (ILD onset or established
ILD, IPF, CTD related ILD, or both), interventions (physicians
involved, instrumental examinations considered during the
MDD) and outcomes evaluated (diagnosis, prognosis, efficacy of
a treatment and other).
RESULTS
The search provided a total number of 333 citations from
Pubmed and 955 from Embase. After excluding duplicates, a total
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FIGURE 1 | Literature search flow chart.
of 952 references were screened for title and abstract and a total of
228 (including one cross reference) for full text analysis. A total
of 29 papers were finally included for data extraction. Figure 1
summarizes the number of papers excluded and the reason for
exclusion. Table 1 summarizes the main characteristics of the
included studies.
Physician Involved in the MDT
In the included studies, the professional figures most frequently
involved in MDT were: pulmonologist (29/29), thoracic
radiologist (26/29), and thoracic pathologist (23/29). The
rheumatologist role was described in 7 studies. Other
professional figures were reported in 7 studies, including:
clinical nurse specialist, cardiothoracic surgeon and lung
transplantation team, occupational therapists, cardiologist,
immunologist, palliative care expert, respiratory therapist,
physiotherapist, and dietitian.
Some studies compared different compositions of MDT.
Lok performed a comparison between a general respiratory
clinic composed only by a pneumologist and a nurse (84
patients) and an ILD clinic setting including a specialist with
interest in ILD with the support of radiologist, pathologist,
and access to transplant and cardiothoracic program (54
patients). A multidisciplinary approach-based follow-up seemed






























TABLE 1 | Characteristics and results of selected studies.
References Study design Population Number of participants Mean age(years)
mean ± SD or (IQR)
Female % Mean follow-up
(months)
Burge et al. (14) Retrospective cohort ILD onset 71 / / /
Chartrand et al.
(15)
Retrospective cohort ILD established, myositis spectrum of
disease, and/or SynS
33 55 22 (66.7%) /
Castelino et al. (16) Retrospective cohort ILD onset 50 64 (32–80) 27 (54%) 12
De Sadeleer et al.
(17)
Retrospective cohort ILD onset 938 60.8 (14–90) 34.8%
Ferri et al. (18) Retrospective case-control UCTD, IPAF, U-ILD 52 UCTD vs. 50 (35 IPAF-
15 U-ILD)
UCTD 55 ± 13, IPAF 63 ±





Flaherty et al. (19) Retrospective cohort ILD onset (CTD excluded) 58 / / /
Fujisawa et al. (20) Retrospective cohort ILD onset (subjected to Surgical Lung
Biopsy)
465 65 35% 7
Han et al. (21) Retrospective cohort Idiopathic ILD 56 56.9 ± 12.6 32 (57.1%) 7




Jo et al. (23) Retrospective cohort Idiopathic ILD 417 31 26.16
Jo et al. (24) Retrospective cohort Idiopathic ILD, ILD related to CTD,
unclassifiable ILD
90 67 ± 11 36 (40%) /
Kalluri et al. (25) Retrospective
case-control/retrospective
cohort
Idiopathic ILD 32 MDC group: 22, no MDC
group: 10





Kohashi et al. (26) Retrospective cohort Idiopathic ILD that underwent to SLB 47 62 (56–67) 14 (29.8%) 1,582
(1,213–1,935)
days
Kondoh et al. (27) Retrospective cohort Idiopathic ILD, Unclassifiable
ILD, NSIP, hypersensitivity
Pneumonia, ILD related to CTD
179 65 (60–70) 56 (31.3%) /
Levi et al. (28) Prospective cohort New onset:
ILD related CTD, Idiopathic ILD, IPAF
60 67.3 ± 12 27(45%) /
Lok (29) Retrospective cohort / 138 General respiratory clinic:
64.6 vs. Patients of ILD
clinic: 55.9
General respiratory clinic 31
(37%)
ILD clinic: 28 (52%)
General respiratory




Retrospective cohort ILD established:
ILD related to CTD, Idiopathic ILD
318 / / /
Nakamura et al.
(31)
Retrospective cohort U-ILD 33 64.4 ± 8.8 17(51.5%) 60.5
Newton et al. (32) Retrospective cohort familial pulmonary fibrosis 115 58 ± 10 57 (49.6%) 180









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































. to give an advantage in terms of survival in patients aged
<60 years, being age an important negative prognostic factors
in this population (29). In the study by Burge et al., the
MDT was composed by a clinical nurse specialist as well as
the classical organization which included specialist radiologist,
histopathologist, and clinician. The authors highlighted the
importance of MDD in the diagnosis of ILD compared to
histology. The 71 patients in the study had in fact undergone
video-assisted thoracoscopic surgery (VATS), and a retrospective
analysis by MDT of the histological, clinical and radiological
data was performed. In 30% of cases after MDD the diagnosis
differed significantly from the histology report, and in a
further 12% MDD changed the diagnosis from probable to
confident (14).
Not all cases must necessarily be submitted to MDD.
Chaudhuri et al. applied the MDD in the retrospective evaluation
of 318 patients. The MDT of this study met weekly, and
only patients sent by ILD expert clinicians were evaluated.
The authors emphasized that after the multidisciplinary
analysis the diagnosis could change, and that in doubtful
cases, where biopsy was not possible due to comorbidities,
the diagnosis could be reconsidered and reviewed over
time based on the evolution and any response to therapy
(30). Flaherty et al. highlighted how in the evaluation of
patients with suspected IPF the review of the case by the
radiologist, pathologist and clinician is fundamental, and that the
sharing of clinical, radiological and possibly histopathological
information can modify the diagnosis and/or increase
diagnostics confidence and interobserver agreement. The
diagnostic process described in this study was in fact organized
through 4 different steps during which more information
were progressively shared and the progressive interaction
between the MDT members was permitted. The agreement
between clinicians and radiologists was thus increased from
the beginning to the end of the diagnostic process (0.39
vs. 0.88) (19).
The multidisciplinary approach, while representing the gold
standard in the diagnosis of ILD, is not always practicable in
normal clinical routine since local structures may not have
experts in this field or meetings may be difficult to organize
due to the geographical distance between the participants or
time-related limits. A solution to overcome these limits could
be provided by digital platforms. Fujisawa et al. validated a
digital platform for the organization of MDD. The clinical
data and radiological and histological images of 465 patients
with suspected ILD (all therefore subjected to SLB) were
included in an electronic database accessible via the web.
Each patient was given a numerical identification code. The
members of the MDT (clinicians, radiologists, and pathologists)
could then separately access the various information and then
a web conference to discuss with the other two members
of the MDT. Also in this study, the MDD made possible
to reformulate the initial diagnosis in a conspicuous number
of cases (49%), and from the analysis of the survival curves
it was shown that also this MDD modality is able to
identify those diagnoses with the worse prognosis (like IPF)
[(20); Table 2].
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TABLE 2 | Physicians involved in the MDT.
References Pulmonologist Radiologist Pathologist Rheumatologist
Burge et al. (14) 1 1 1 0
Chartrand et al. (15) 1 1 1 1
De Sadeleer et al. (17) 1 1 1 1
Ferri et al. (18) 1 1 1 1
Kondoh et al. (27) 1 1 1 0
Levi et al. (28) 1 1 1 1
Jo et al. (24) 10/1/2019 9:37:00 p.m. 1 1 1 1
Flaherty et al. (19) 1 1 1 0
Fujisawa et al. (20) 1 1 1 0
Han et al. (21) 1 1 1 0
Jo et al. (42) 1 1 1 0
Kohashi et al. (26) 1 1 1 0
Lok (29) 1 1 1 0
Chaudhuri et al. (30) 1 1 1 0
Nakamura et al. (31) 1 1 1 0
Patterson et al. (3) 1 1 1 0
Pezzuto et al. (33) 1 1 1 0
Tanizawa et al. (34) 1 1 1 0
Thomeer et al. (35) 1 1 1 0
Tomassetti et al. (36) 1 1 1 0
Tominaga et al. (37) 1 1 1 0
Oltmanns et al. (38) 1 1 1 0
Walsh et al. (40) 1 1 1 0
Yamauchi et al. (41) 1 1 1 0
Jeong et al. (22) 1 1 0 1
Newton et al. (32) 1 1 0 0
Ussavarungsi et al. (39) 1 1 0 0
Castelino et al. (16) 1 0 0 1
Kalluri et al. (25) 1 0 0 0
Variables Evaluated During MDD
Clinical history assessment is reported in 24 of the 29 included
studies. In addition to demographics (age and sex), the
most frequently collected data concerned smoke (17/29) and
environmental exposure (11/29). The evaluation of symptoms
related to the possible presence of CTD and physical examination
were reported in 7 studies.
High resolution computed tomography (HRCT) was
evaluated in all studies except two: one dealing with a
multidisciplinary approach not for the diagnosis, but for
palliative care of ILD patients (25), and one focused on
transbronchial lung cryobiopsy (39). HRCT was usually acquired
only at baseline during the diagnostic process (24/27 studies).
In 3 studies including longitudinal information, HRCT was
repeated after 3–6 months in two studies (22, 31), and not
specified in one study (35). Baseline chest X-ray was described in
only one study (37).
Pulmonary function tests (PFT) were part of the core set
of parameters analyzed during multidisciplinary evaluation in
almost all studies (27/29). PFT were not performed in the same
two previously described studies, in which even HRCT was not
performed (25, 39). In 21 studies, PFTs were performed only at
the baseline while in 6 studies repetition was described during
follow-up with different timing: 1–3 months (38), 3 months
(22), 3–6 months (31), annually (27), and not specified (32).
The parameters considered were in most cases the forced vital
capacity (FVC), the ability to spread carbon monoxide (DLCO)
and forced expiratory volume in the 1st second (FEV1); less
frequently, total lung capacity (TLC); and residual volume (RV).
Pulmonary histology was evaluated in 21 studies. The role in
the MDD of biopsy and especially of two different techniques
(namely surgical lung biopsy SLB, and bronchoscopic lung biopsy
BLC) was evaluated in a cross-sectional study involving 171
patients (58 BLC vs. 59 SLB). Both the modalities of biopsy
increased the diagnostic accuracy of IPF (36). Ussavarungsi
evaluated the role of Transbronchial Cryobiopsy (TBC) in
the MDD; in this series of 74 patients, TBC failed to
obtain histological samples demonstrating a specific UIP or
NSIP pattern (39). In a retrospective cohort of 124 patients
with suspected IPF, authors suggested to perform HRCT at
baseline together with PFT (FVC, TLC; RV and DLCO),
laboratory test for CTD and vasculitis, and bronchoalveolar
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lavage (BAL) for cytological and microbiological tests. HRCT
results were then reviewed by MDT and classified according
to the ATS/ERS/JRS/ALAT guidelines in UIP pattern, probable
UIP and inconsistent with UIP patterns. Only in the last two
and in presence of clinical, immunological, microbiological,
and cytological abnormalities suggestive for IPF, the authors
recommended biopsy. 15/124 patients could not be classified in
neither of proposed definitions of HRCT patterns, but they were
subsequently diagnosed with IPF after MDD and biopsy (33).
Serological data were reported in 17/29 studies, and 14
included autoantibody profile tests, especially RF, ACPA,
ANA, antibodies against extractable nuclear antigens (ENA),
myositis specific antibodies (including anti-synthetase) and
myositis associated. Two studies reported genetic evaluation.
Newton correlated traditional parameters evaluated duringMDD
(demographic data, physical examination, PFT, and HRCT) with
four telomere-related genes mutations (TERT, TERC, RTEL1,
and PARN). These genetic investigations were not usually
performed during the traditional MDD for ILD, but this study
focused on the evaluation of hereditary forms of pulmonary
fibrosis (32). Another genetic test relating the MUC5B gene
(rs35705950), associated with susceptibility to IPF, was obtained
in a study cohort involving 252 ILD patients considered
through MDD for diagnosis. In this study, the presence of
bronchiolocentric fibrosis seemed not to correlated with MUC5B
gene, telomere length, and IPF diagnosis formulated through
MDD (34).
Further instrumental investigations evaluated during
MDD were described in 15 studies, including BAL, doppler
echocardiography, and 6-min walking test (Table 3).
Outcome Evaluated by MDT
Fifteen studies had as outcome a reference standard diagnosis,
7 prognostic evaluation, 5 both diagnosis and prognosis, 1
evaluated efficacy of pirfenidone treatment, and 1 the effect of
multidisciplinary approach on patient perception of the disease.
Evaluating in detail the studies in which the outcome was
the diagnosis, after the assessment by the MDT of a large
cohort of 417 patients collected in the Australian IPF Registry
(AIPFR), it was shown that in 23% of cases the guidelines
for IPF were not applied by referring physicians (42). Despite
this observation, in another study by the same authors the
MDD showed to be relevant not only for the diagnosis, but
also for the investigations prescribed and therapeutic behavior.
After multidisciplinary evaluation of 93 patients, in fact, ILD
diagnosis was changed in 53% of patients referred, and 71% of
unclassifiable disease were re-classified under a specific diagnosis
with obvious implication on therapeutic approach including an
increased recommendation for anti-fibrotic therapy and referral
for clinical trials (24). In a larger study by De Sadeleer involving
938 patients sent for multidisciplinary evaluation, the diagnosis
was reached in 79.5% and modified in 41.9% of cases after
MDD, while a diagnostic conclusion was not achieved only in
19.5% of the patients; however, in this case further investigations
(16% of the total court) were at least suggested. This study
demonstrated that a correct diagnosis also correlated with better
prognosis, and that MDT could be helpful for the identification
of those patients with worse prognosis. Indeed patients who
were diagnosed as IPF demonstrated a worse prognosis than
those classified as not-IPF after MDD [Hazard ratio (HR) 4.31,
p<0.001], while patients initially classified as IPF who reported a
change in their diagnosis after MDD showed a better prognosis
compared to patients definitely diagnosed with IPF (HR 0.37,
p = 0.094) (17). In another study of 33 patients with previous
diagnosis of unclassifiable-ILD (U-ILD), clinical, radiological and
histological data were retrospectively evaluated by MDT. After
MDD, the initial diagnosis was confirmed in 18 (54.5%) patients,
but changed to collagen vascular disease-related interstitial
pneumonia in 9 (27.3%), to chronic hypersensitivity pneumonitis
in 3 (9.1%), to idiopathic pleuro-parenchymal fibroelastosis in 2
(6.1%), and IPF with emphysema in 1 (3.0%) patient (31).
The importance of cooperation between clinicians,
radiologists and pathologists was reinforced by the analysis
of patients enrolled in the IFIGENIA trial, a randomized
placebo-controlled trial conducted on patients with IPF in
which N-Acetylcysteine was associated referred to standard
therapy (azathioprine plus steroid). Patients diagnosed as IPF
by the clinician were subjected to a commission of thoracic
radiology experts who evaluated chest HRCT images and by
expert pathologists who evaluated the results of biopsies if
performed. The diagnosis of IPF was rejected in 12.8% of cases
formulated by the expert clinician after reviewing the histology
and HRCT images thus demonstrating the importance of
the multidisciplinary collaboration between clinicians, expert
radiologists, and pathologists for a correct diagnosis of IPF (35).
The reliability of MDD composed by these professional figures
was also assessed. Seven different MDTs assessed 70 cases, for
a total of 490 diagnoses [CTD-related ILD (n = 146), IPF (n
= 88), idiopathic NSIP (n = 50), hypersensitivity pneumonitis
(n = 46), and others (n = 160)]. Inter-MDT agreement for
a first-choice diagnosis of IPF was good (κ = 0.60), good for
CTD-related ILD (κ = 0.64), but fair for idiopathic NSIP (κ =
0.25), and hypersensitivity pneumonitis (κ = 0.24). The authors
therefore recognized the excellent performance of the MDT in
diagnosing IPF for which better defined classification criteria
are available than for other conditions, i.e., hypersensitivity
pneumonitis. Furthermore, the highest frequency of CTD-ILD,
demonstrated the importance of including a rheumatologist in
the multidisciplinary evaluation of ILD (40).
Besides the diagnostic process, MDD could be performed
to evaluate the prognosis of particular populations of ILD
patients. In a prospective cohort study involving 327 subjects,
multidisciplinary approach was employed to evaluate the role
of age onset to determine both diagnosis and prognosis of ILD
patients (3). MDT can also be used not only in the diagnosis
of IPF but also to identify sub-populations of patients with a
worse prognosis. In a study conducted on 47 patients with IPF
confirmed after SLB and MDD, the multidisciplinary evaluation
allowed to identify the presence of emphysema and its extent as
negative prognostic factors for survival (26). In the evaluation
of the patient’s suitability for starting pirfenidone therapy,
the multidisciplinary meeting, where clinicians, radiologists
and pathologists discussed clinical and instrumental data, was
essential to identify IPF patients (38).






























TABLE 3 | Variables evaluated during MDD.
References Clinical evaluation HRCT PFT Lung biopsy Laboratory test Other
Burge et al. (14) History (brief clinical history, the duration of









Yes Immunological tests to identify
collagen-vascular diseases, antibodies
associated with hypersensitivity





History (smoke, family history)
BMI
Yes at baseline Yes, FVC, DLCO No 5 myositis-specific (Jo1, PL12, PL7, OJ,
EJ, Mi2, SRP) and myositis-associated
antibodies (Ro52, Ku, PM-Scl) antibodies
(Jo1, PL-7, PL-12, EJ, OJ), 2 other
myositis-specific antibodies (Mi-2, SRP),
and 3 myositis-associated antibodies (Ku,
PM-Scl, Ro-52)
/
Castelino et al. (16) History (occupational and environmental
exposures, medication history, family
history)




Yes at baseline Yes, FVC, DLCO Yes Anti-nuclear antibody (performed using
HEp2 cell lines at BWH), ENAs, RF,
inflammatory markers (ESR and CRP)
-Nailfold capillaroscopy
-Echocardiography
-Esophageal testing for pH or
manometric studies
De Sadeleer et al.
(17)
History (familial history, exposures,
comorbidities, and medication use)
-Physical examination
Yes at baseline Yes not specified Yes Serological data (not specified) BAL
Ferri et al. (18) - History (demographic, occupational,
smoking, medication, environmental,
occupational, autoimmune manifestation)





ANA, anti-ENA, ESR, CRP, routine blood
chemistry, urinalysis, infections, RF (first
line), antiCCP, complement, ASMA, AMA,
ANCA, antiphospholipid, organ specific




Salivary gland echography, Minor
salivary gland biopsy, Muscle
biopsy, Electromyography
Flaherty et al. (19) History (symptoms, environmental
exposures, comorbid illnesses, medication
use, smoking history, family history)
-Physical examination findings
Yes at baseline Yes, lung volumes
and DLCO
No Serological data (not specified) /
Fujisawa et al. (20) History (symptoms, environmental











Han et al. (21) - History [smoking history; environmental,
occupational and drug exposure; history
of established connective tissue
disease (CTD)]













































































TABLE 3 | Continued
References Clinical evaluation HRCT PFT Lung biopsy Laboratory test Other
Jeong et al. (22) - History (exercise status, Educational
status, underlying rheumatic diseases)











Jo et al. (42) History (smoke, presence of underlying
rheumatic diseases)
-Physical examination(BMI)




Jo et al. (24) -History smokers (pack/years) Yes at baseline Yes, FVC, TLC,
DLCO
Yes Extended myositis screen and
hypersensitivity precipitins and BNP




Kalluri et al. (25) -Charlson Comorbidity Index
-Pharmacotherapy (anti fibrotics, PPI,
opioids, benzodiazepines)
No Yes, FVC, DLCO No No /
Kohashi et al. (26) -History (smoke)
- BMI
Yes at baseline Yes, FVC, FEV1,
FEV1/FVC, DLCO
No BNP, LDH, KL-6, SP-D, ANA, RF, other
autoantibodies
echocardiography




Yes No BAL, PaO2
Levi et al. (28) -History (smoke, family history of ILD,
medications and environmental
risk factors)
Yes at baseline Yes, FVC%,
DLCO%, and
TLC%
Yes Complete blood count, chemistry, renal
and liver function tests, antinuclear
antibody, rheumatoid factor (RF),
C-reactive protein (CRP), anti-dsDNA,
Scl70, anti-SSA, and anti-SSB were done.
A cyclic citrullinated peptide (CCP)
antibodies test was done in the case of a
positive RF result, anti-Jo1, anti-RNP,
anti-Smith, anticentromere,
antimyeloperoxidase, antiproteinase−3,
and anticardiolipin antibodies, erythrocyte
sedimentation rate, various IgG
subclasses including IgG4, and vitamin D
(level)
Echocardiogram (Pulmonary
hypertension, right heart failure),
O2 saturation, Bronchoscopy
(BAL only, TBB, Cryobiopsy,
EBUS), 6-min walking distance
(6MWD) test,
Lok (29) -Evaluation of ongoing
pharmacologic therapy











-Evaluation of Smoking index






Yes Krebs von der Lungen-6, surfactant
protein D, antinuclear antibody,















































































TABLE 3 | Continued
References Clinical evaluation HRCT PFT Lung biopsy Laboratory test Other
Newton et al. (32) History (ethnicity, clinical manifestations:
dyspnea, cough, smoking status)
-Physical examination (crackles, clubbing)






Patterson et al. (3) -History (race, smoking habits, clinical
features of sarcoidosis, hypersensitivity
pneumonitis, and CTD related ILD)
Yes at baseline Yes, FVC, and
DLCO at baseline
and yearly
Yes No Walking distance, Hypoxemia
Pezzuto et al. (33) No Yes at baseline Yes, at the time of
evaluation FVC,
TV, TLC, DLCO
Yes For exclusion of CTD and vasculitis but not
specified
BAL
Tanizawa et al. (34) -History (ethnicity/race, smoking status,
selected comorbidities) (asthma;
congestive heart failure; gastroesophageal












Yes No MUC5B genotyping and
telomere length measurement




No Yes No /
Tomassetti et al.
(36)
-History: onset, symptoms, detailed
history of exposure, family history, past
medical history, and medications
Yes at baseline Yes, at the time of
evaluation FVC,
RV, TLC, DLCO
No Blood cell count, LDH, CRP, ESR, liver





-History: onset, symptoms, detailed
history of exposure, family history, past
medical history, and medications
Yes, baseline Yes VC, DLCO Yes Rheumatoid arthritis test, rheumatoid
arthritis particle agglutination (RAPA) and
ANA, serum biomarkers (Krebs von der




-History (comorbidities, smoking history) Yes at baseline / Yes Blood gas analysis, liver function test /
Ussavarungsi et al.
(39)
No No / Yes No /
Walsh et al. (40) -History (smoking habits, rheumatological
disease, and
rheumatological manifestation)
Yes at baseline / Yes Autoantibodies /
Yamauchi et al.
(41)
-History (smoke) Yes at baseline / No KL-6, SP-D /
CT, computer tomography; BMI, body mass index; FVC, forced vital capacity; DLCO, the ability to spread carbon monoxide; FEV1, forced expiratory volume in the 1st second; less frequently, TLC, total lung capacity; CRP, C-reactive
protein; ESR, erythrocyte sedimentation rate; ANA, antinuclear antibodies; RF, rheumatoid factor; ACPA, anti-cyclic citrullinated peptide; ENA antibodies against extractable nuclear antigens; BAL, bronchoalveolar lavage; ASMA, antibodies
against smooth muscle; ANCAs, anti-neutrophil cytoplasmic antibodies; CTD, connective tissue disease; SLB, surgical lung biopsy; 6mwt, six minute walking test; ILD-CTD, interstitial lung disease related to connective tissue disease;
IPF, idiopathic pulmonary fibrosis; SpO2, saturation of peripheral oxygene; BNP, natriuretic peptide B; LDH, lactic dehydrogenase; KL-6, Krebs von den Lungen 6; SP-D, surfactant protein-D; NSIP, idiopathic non-specific interstitial
pneumonia; IPAF, interstitial pneumonia with autoimmune features; TBB, transbronchial biopsy; Scl70, anti-topoisomerase1; EBUS, endobronchial ultrasound; PaO2, Partial Pressure of Oxygen in Arterial Blood; U-ILD, undifferentiated
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Possible applications of MDD could encompass the
management of ILD patients. In a study by Kalluri, subjects
with ILD secondary to rheumatic diseases referred to the
MDT (composed of pneumologist and rheumatologist), were
compared with patients suffering from IPF followed according
to a normal care setting. While the disease progression assessed
through the worsening of the HRCT and PFT parameters was
comparable, patients evaluated by MDD experienced greater
satisfaction and more participation in their care path (22).
A multidisciplinary approach in palliative care involving the
participation of ILD experts, a palliative respiratory care expert,
nurse, respiratory therapist, physiotherapist, and a dietitian,
compared to the standard approach (namely ILD experts and a
nurse) proved efficacy in improving the management of a small
series of 32 patient, in terms of reduced number of emergency
visits and hospital admissions (25).
There is little evidence concerning the role of MDT activity
in the follow up. The diagnosis of ILD can change over time in
light of new clinical or serological elements that may emerge in
the course of the disease, as well as the progress and response
to therapy. In a retrospective study of 56 patients evaluated
during a 7-month average follow-up, it was shown how the re-
evaluation of new clinical elements and a second HRCT by the
pulmonologist and radiologist can modify the diagnosis of a
first multidisciplinary discussion (10.7%), as well as the level
of agreement (25% of cases). The multidisciplinary evaluation
should therefore be a dynamic process not limited to the initial
phase of the diagnostic process but also considered during the
follow up (21). In a retrospective cohort study, 30 patients with
a probable UIP pattern on HRCT and histology compatible or
probable for UIP were identified by MDD. The evolution of
the radiological data and the prognostic implications of patients
who evolved radiologically were therefore evaluated against a
specific HRCT pattern. In this case, the MDT and in particular
the interaction between the radiologist and pathologist was
fundamental to identify the target population of this study (41).
Role of Rheumatologist
The rheumatologist was included in MDT in 7 studies. The
retrospective study by Chartrand highlighted the role of the
rheumatologist in the MDT while evaluating patients with
ILD. From the National Jewish Health Metical database, the
authors identified patients initially referred as IPF. After the
multidisciplinary evaluation, the diagnosis was modified in
33 patients in ASSD (27/33) or a myositis spectrum disease
(6/33). In these patients the identification of specific myositis
antibodies (in particular anti-synthetase) or myositis associated
were fundamental. The authors underlined that about a third
of the patients was ANA negative, and so the research of the
autoimmune profile should be extended to these antibodies that
often recognize cytoplasmic antigens. Moreover, in 85% of cases
at least one manifestation attributable to CTD was present,
such as Raynaud’s phenomenon, mechanic’s hand, Gottron’s
papules, capillaroscopic alterations. Among these, the muscular
manifestations were present only in a third of patients (15).
A retrospective observational study of 50 patients, the MDD
led to a final diagnosis of CTD-ILD in 25 patients, IPF in 15
and other forms of ILD in 10. In particular, in 7 of the 25
patients with CTD-ILD the pre-MDD diagnosis was IPF with
completely different prognostic and therapeutic implications.
Therapy therefore changed in 20 of 25 patients with CTD-ILD
and in 4 of 15 patients with IPF after MDT evaluation (16). In the
study by Ferri et al., theMDDwas performed by a rheumatologist
and a pneumologist. Other professional figures such as the
thoracic radiologist, surgeon and pathologist were considered
only in selected cases. Given the type of setting, the authors
described a more detailed clinical and laboratory assessment
set with particular attention to the evaluation of autoimmune
clinical manifestations and serological investigations. In the
evaluation of the patient, specific instrumental investigations
were also included, such as nailfold capillaroscopy, joint and
salivary glands ultrasound, suggesting an application based on
clinical suspicion (18). In a prospective study of 60 patients the
role of the rheumatologist in the classification of patients with
ILD at the onset is again emphasized. The diagnostic process was
divided into three phases: a first phase in which the traditional
MDT was involved, consisting of pulmonologist, radiologist and
pathologist, and a second one where a rheumatologist evaluated
the cases independently. In the course of traditional MDD
clinical information, PFT, HRCT, biopsy, and BALwhen available
were evaluated. Serological investigations routinely performed
included ANA, anti-dsDNA, anti-topoisomerase-1(Scl70), anti-
SSA, and anti-SSB, ACPA (done in the case of a positive
RF result). To these tests, the following could be added after
the rheumatologic evaluation: anti-Jo1, anti-RNP, anti-Smith,
anticentromere, ANCA, and anticardiolipin antibodies, various
IgG subclasses including IgG4. Also anti-synthetase antibodies
were tested if deemed necessary by the rheumatologist. Finally,
there was a third phase of comparison between MDT and
rheumatologist, in which some diagnoses formulated by the
MDT were modified. In particular 21.9% of IPF cases and 28.5%
of hypersensitivity pneumonia cases (HP) the diagnosis was
modified in favor of pathologies of rheumatological interest such
as Sjogren’s syndrome, associated ANCA-associated vasculitis,
RA, ASSD, SSc, and related IgG4 pathology. The authors also
argued that the rheumatological evaluation could have avoided
7 bronchoscopies and 1 lung biopsy (28).
DISCUSSION
Before the publication of the 2002 ATS guidelines, the
diagnosis of ILD was based on histopathology. However,
the interobserver agreement between expert histopathologists
was reported low, especially in the presence of non-specific
interstitial pneumonia (NSIP) pattern (43). The level of
diagnostic accuracy and interobserver agreement between
radiologists was better than between pathologists, and HRCT
is currently the most used diagnostic tool in the evaluation
of patients with ILD, being less invasive than lung biopsy.
Furthermore, different histopathological findings may be present
in different lobes of the same patient. Already before the
publication of ATS/ERS/JRS/ALAT guidelines, the importance
of a multidisciplinary evaluation of IPF patients was proposed
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(29). Current clinical practice guidelines suggest that in patients
with suspected IPF a definite UIP pattern at HRCT could be
considered a sufficient criterion for making the diagnosis. About
half of the patients, however, presents a probable or inconsistent
UIP pattern. In this group of patients the MDT is fundamental
(44), especially for the identification of IPF which is the form
of ILD with the worst prognosis with an average survival of 2–
3 years from diagnosis. Given the current availability of effective
anti-fibrotic drugs such as nintedanib and pirfenidone, a correct
and early diagnosis of IPF is crucial (5).
SLB is generally considered in cases where imaging is
inconsistent with UIP and in case of conflicting clinical data.
Nevertheless, an UIP patter at histology is not necessarily
indicative of IPF as demonstrated in the study by Tominaga,
where the clinical information and HRCT images of 95 patients
diagnosed as IPF and confirmed by a histological pattern
compatible with UIP, were first re-evaluated separately and
later on the course of MDD by a group of radiologists and
pulmonologists. The two groups were progressively provided
withmore clinical data and radiological images.With the increase
of clinical and radiological information, the degree of certainty in
the diagnosis was reduced to a low or to an intermediate level in
41% of cases (37).
Multidisciplinary evaluation is essential in patients who do not
have a definite UIP pattern at HRCT. Especially for probable UIP
pattern, different studies have reported a variable frequency of
IPF from 90 to 60%. Given the prognostic importance of a correct
diagnosis, integration of imaging with clinical and histological
data is fundamental, as demonstrated in a cohort of 179 patients
with probable UIP pattern at HRCT in which the 50% of cases
were diagnosed by MDD as IPF presenting worse prognosis
compared to patients without IPF (27).
MDT classically include a pulmonologist, a radiologist
and pathologist expert in ILD, but other professional figures
including specialists in rheumatology, thoracic surgery, lung
transplantation, and occupational medicine are often involved
on demand (17). Despite the importance of MDD and available
recommendations, there are no indications on the optimal
composition of the MDT, on the timing or how to organize these
meetings. Although in most cases the MDD aims to make an
accurate diagnosis of ILD, the multidisciplinary approach can be
used in patient care or for follow-up. Depending on the aims and
degree of experience of the MDT itself, the organization may be
different. For example, members of a recently established MDT
could meet more frequently while in the case of clinicians with
more experience in multidisciplinary discussion, the assessment
could only be performed in selected cases. Depending on the
purpose of the MDD, the members could be different, for
example in the diagnostic evaluation the thoracic surgeon might
not be useful (44).
Despite the recommendations and the available studies, it is
currently not known whether the multidisciplinary approach is
better than the single expert’s clinical judgment in the diagnosis
of patients with ILD. Moreover, the strict application of the
guidelines for IPF is not always feasible; for example it is not
always possible to perform SLB for safety reasons, and in the
definition of the UIP pattern (both radiological and pathological)
often the agreement between the observers is only moderate.
Finally, the guidelines do not indicate how some clinical aspects,
which may help to increase diagnostic confidence, should
be included in MDD. This means that the multidisciplinary
approach is not always applicable, and often the diagnosis is
left to the opinion of the expert. The concept of “working
diagnosis” recently proposed by the Fleischner Society allows to
justify a disease-specific therapy despite a non-definite diagnosis
(45). The lack of a standardized ontological framework can
also determine heterogeneity in diagnosis for patients with ILD.
Ryerson et al. made a proposal to standardize the terminology,
by subdividing according to the degree of diagnostic confidence
(> 90%, between 89 and 50% and <50%) the wording in the
diagnosis of ILD in “confident,” “provisional,” and “unclassifiable
ILD” (46). An international study involving 404 physicians that
evaluated 60 cases of suspected IPF employed these standardized
definitions to evaluate the impact of diagnostic likelihood on
physician’s decision to performed biopsy and on which treatment
prescribe. This study showed that in presence of a provisional
high confidence IPF diagnosis only a minority of patients (29.6%)
would be addressed to SLB. Furthermore, most physicians
prescribed anti-fibrotic therapy without performing histological
evaluation in 63% of patients with a diagnostic likelihood of 70%,
and in 63.0 and 41.5% of provisional high confidence and low
confidence IPF diagnoses, respectively. The behavior of experts
participating to this study was in most cases different from the
guidelines; for instance, especially university hospital physicians
tended not to require biopsy and to choose therapy according to
a “working diagnosis” instead of a certain diagnosis as defined by
the current guidelines. Therefore, the MDD would have a role in
training physicians especially when they work in isolation (47).
The ATS guidelines emphasize the need to exclude the
presence of a CTD during the evaluation of a patient with
ILD. Despite this recommendation, rheumatologists are not
considered mandatory among professional figures involved in
the MDD, reserving the rheumatological evaluation only to
patients with positive autoantibody serology, suspicious clinical
manifestations for CTD and other rheumatological diseases,
or in case with demographic characteristics atypical for IPF
(e.g., female, age younger than 60 years, not smokers). The
presence of a rheumatologist could therefore be fundamental
in identifying specific non-pulmonary clinical manifestations
that could not be easily recognized by traditional members
of MDT, especially in patients with demographic, clinical
and histopathological features inconsistent with IPF (15). For
example, in female patients younger than 50 years, a diagnosis
of IPF is unlikely compared to a male smoker over 60.
Furthermore, some radiological patterns such as NSIP or
organizing pneumonia (OP) are more characteristic of ILD
associated with CTD. The presence of a definite UIP pattern,
however, does not exclude the presence of an underlying
autoimmune disease especially RA and some cases of SSc
(48). Histological UIP pattern is indistinguishable between
IPF and CTD-ILD, but some characteristics such as increased
expression of lymphoid hyperplasia with germinal centers,
more plasmatic infiltration, and less severe honeycombing are
typical for CTD.
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FIGURE 2 | Proposal for a multidisciplinary team (MDT) involving the rheumatologist. (a) Checklist regarding signs and symptoms compatible with CTD or arthritis. (b)
First line serological test: RF, ACPA, ANA, CPK. (c) Second line serological test: Anti-ds DNA, Anti-Ro (SS-A), Anti-La (SS-B), Anti-ribonucleoprotein,
Anti-topoisomerase (Scl-70) Anti-tRNA synthetase, Anti-PM-Scl, Anti-MDA5.
ILD can be a manifestation developed during an established
CTD, so the diagnostic approach, therapy, and follow-up are
better defined, and the rheumatologist is naturally involved in
patient management. In other contexts, ILD may be the first
manifestation at the onset of a not recognized CTD and the
other typical clinical features may appear after the pulmonary
involvement. This is known for example, especially in myositis
spectrum disorders where in 10–30% of cases ILD may be the
predominant manifestation (10), in particular in case of ASSD
where the classical triad arthritis, myositis and ILD may develop
during the follow up (49). The lack of specific classification
criteria for ASSD makes the correct diagnosis for these patients
more difficult, and an expert rheumatologist would be essential
during the evaluation of these patients (12). Moreover, very few
patients affected by SSc or RAmay present as ILD at the onset, so
in these cases the diagnostic process could be very challenging.
In these pathological contexts the rheumatologist is crucial to
identify the signs and symptomsmore nuanced and less clear that
cannot be recognized by other professional figures traditionally
involved in the MDT.
The evaluation of the patient with ILD cannot be independent
of the execution of blood tests, in particular autoimmunity,
and different guidelines have proposed the execution of
different biochemical test. The French guidelines recommends
to evaluate complete blood cell count, CRP, serum creatinine,
transaminases, γ-glutamyltransferase, and alkaline phosphatases,
ANA, ACPA, and RF, reserving the search of other more
specific antibodies (anti-SSA, anti-SSB, anti-centromeres, Scl70,
anti-U3RNP, anti-synthetase antibodies, anti-thyroid antibodies)
in case of positivity of first line antibodies or in presence
of clinical manifestation compatible with CTD (50). The
ATS/ERS/JRS/ALAT guideline recommends CRP, ESR, ANA (by
immunofluorescence), RF, myositis panel and ACPA performing
other test according to symptoms and signs (8). In the last few
years, the diffusion of laboratory kits able to identify specific
and associated myositis antibodies has made possible to reclassify
patients with doubtful clinical pictures especially in the presence
of negative ANA or with cytoplasmatic patterns. In particular
antibodies such asMDA-5 and specific anti-synthetase antibodies
such as PL2 and PL7 identify myositis with prevalent pulmonary
expression that could be the first clinical manifestation up to
10–30% of cases of myositis spectrum disease (10).
The studies included in this review show that there is not
a common behavior in serological evaluation, and only in 17
studies biochemical tests were evaluated during MDD. Fourteen
studies reported the evaluation of autoantibodies without a clear
suggestion of which test should be performed, and in 5 studies is
not reported which serological test was chosen.
Another diagnostic challenge is represented by IPAF, a clinical
entity of more recent characterization and of which classification
criteria have been formulated (13). IPAF could be considered an
ILD in which clinical or serological abnormalities typical of CTD
are present but insufficient to satisfy classification criteria of a
defined autoimmune disease. These classification criteria share
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many characteristics with undifferentiated connective tissues and
allow to identify as IPAF very different clinical entities including
patients with very early SSc or other CTD such as myositis
spectrum diseases with a predominant pulmonary manifestation
at onset. This could result in a mis-classification of patients
especially without a rheumatologic evaluation (51).
Despite these considerations, no clear indications are
available about the rheumatologist involvement in MDT.
Only 7/29 studies included in this review described a
rheumatological evaluation during MDD paying attention
to the correct re-classification of patients who were initially
classified as IPF (15, 16), and to the possibility of avoiding
not necessary diagnostic procedures (28). From the available
studies it is not possible to identify a univocal attitude on the
modalities and timing of involvement of the rheumatologist in
such a context.
For these reasons we have formulated a proposal for the
organization of the MDT that provides different scenarios to
suggest when and how the rheumatologist should be included
in MDD, especially to help to identify CTD-ILD and IPAF
(Figure 2). A first scenario includes ILD patients with HRCT
pattern typical for UIP which is less frequent in cases of
ILD associated with autoimmune diseases and more typical
of IPF. However, it is still possible that a UIP pattern could
be found, even if less frequently, in course of rheumatological
disorders, especially RA and SSc. We have therefore proposed
that the pulmonologist participating to MDT should be trained
to identify clinical manifestations compatible with CTD or RA
belonging to the checklist reported in Table 4. This core set
includes main signs and symptoms typical of rheumatologic
diseases that can be more frequently complicated with ILD:
SSc, RA, Sjogren syndrome, and myositis spectrum disorder.
For joint involvement, we have decided to include patients
presenting at least one swollen or tender joint on examination
excluding distal interphalangeal joints, first carpometacarpal
joints, and first metatarsophalangeal in agreement with the
definition reported in 2010 classification criteria for RA (54).
For myositis spectrum disorders we have included the search
for weakness of proximal musculature of the upper and lower
limbs and for the presence of typical cutaneous manifestations
(Gottron’s papules and sign) described in the classification
criteria of 2017 for idiopathic inflammatory myopathies (53).
To identify patients affected by ASSD, fever, mechanic’s hands,
Raynaud’s phenomenon and dysphagia have been included in
the checklist. In particular, the last two manifestations together
with puffy fingers, sclerodactyly, and telangiectasias, belong to
scleroderma spectrum manifestations and so they should be
considered as part of the coreset of clinical manifestations
to be evaluated during diagnostic approach of patients with
ILD. Finally, the sicca syndrome has been described according
to the 2002 classification criteria for Sjogren’s syndrome as
a sensation of daily dryness, ocular or oral duration longer
than 3 months (52). In case of positivity of at least one
of these clinical criteria, we have proposed to involve the
rheumatologist for a second evaluation in order to confirm
the first clinical impression and therefore to perform further
instrumental examinations, such as biochemical tests (including





Joint involvement Any swollen or tender joint on examination
excluding distal interphalangeal joints, first
carpometacarpal joints, and first
metatarsophalangeal joints are excluded from
assessment. Synovitis could be confirmed by
imaging (Definition according 2010 Rheumatoid
Arthritis Classification Criteria)
Raynaud syndrome A vascular disorder especially of the fingers and
toes, that is characterized by pallor, cyanosis,
and redness in succession usually upon
exposure to cold
Puffy fingers or sclerodactyly Swelling or thickening of fingers
Distal digital tip ulceration Loss of epithelialization and tissues involving, in
different degrees, the epidermis, the dermis,
the subcutaneous tissue, and sometimes also
involving the bone
Telangiectasia Small dilated-blood vessels near the surface of
the skin or mucous membranes, measuring
between 0.5 and 1ml in diameter, especially
localized on finger or face
Mechanics hand Rough, cracked, hyperkeratotic, aspect of
palmar areas of the fingers with fissures of
the skin
Sicca syndrome Sensation of dryness of eyes and/or mouth
daily and persistent for 3 months (52)
Gottron signs Fixed rash or patches on the extensor surfaces
of the joints (especially elbows and/or knees)
Gottron papules Erythematous to violaceous papules and
plaques over the extensor surfaces of the
metacarpophalangeal and
interphalangeal joints
Eliotrophic rash Violaceous erythema of the upper eyelids often
with associated edema and telangiectasia
Fever Unexplained by other causes
Muscle weakness Weakness of proximal upper and lower
extremities as Distal muscles are less involved.
Weakness of neck flexors is usually more
severe than of neck extensors (53)
Dysphagia Difficulty in swallowing
autoantibodies), capillaroscopy or echography suggested by
the rheumatologist based on his clinical suspicion, thus
avoiding useless and expensive investigations. Furthermore,
this approach makes it possible to identify IPAF. According
to the ATS classification criteria, in fact, being absent the
morphological domain [HRCT pattern compatible with NSIP,
OP or LIP (lymphoid interstitial pneumonia)], both the
serological and the clinical domain are required. Therefore,
our checklist including all the manifestations present in the
clinical domain of these criteria, allows to identify patients with
suspected IPAF and to confirm the suspicion after performing
serological investigations.
Another scenario includes ILD patients with probable
UIP pattern, indeterminate UIP pattern on HRCT. In this
case, patterns frequently observed during CTD as NSIP, OP,
Frontiers in Medicine | www.frontiersin.org 14 October 2019 | Volume 6 | Article 246
Furini et al. Rheumatologist’s Role in ILD Diagnosis
and LIP would be included so the probability to observe an
ILD secondary to an autoimmune disease is greater than
in case of typical UIP pattern. For this reason, we have
added to the clinical domain a biochemical screening test
including ANA, RF, ACPA, and creatine phosphokinase
(CPK). In case of negativity of both clinical and serological
domain, patients presenting NSIP, OP, or LIP pattern are
subjected to further serological evaluation in order to exclude
IPAF or myositis spectrum disorders, and evaluated by a
rheumatologist. In case of positivity of at least one of clinical
or serological parameters during the screening, patients would
be referred to rheumatologist that would suggest to perform
further instrumental investigations such as biochemical tests
(including autoantibodies), capillaroscopy, or echography
based on clinical suspicion in order to avoid unnecessary
investigations and to accurately diagnose patients with
CTD-ILD (Figure 2).
CONCLUSION
The role of the rheumatologist in MDD for the evaluation of
patients with ILD is still not defined but could be fundamental
for the correct diagnosis of CTD-ILD and IPAF. From the
literature review, it emerges that in most cases the MDT is
composed by the pulmonologist, radiologist and pathologist. The
first being an essential member of the MDT, could be trained
to be able to identify patients with suspected CTD-ILD and
IPAF in order to select them for rheumatological evaluation.
This organization could simplify the multidisciplinary meeting,
reducing the times in which all professions are required for
MDD. Our proposal for the organization of the MDT also
provides a minimum core set of blood tests for screening,
reserving the execution of second-level investigations only after a
rheumatological indication and targeted according to the clinical
suspicion, thus avoiding unnecessary and confounding tests.
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